Evolved By Nature Inc. has begun highlighting the commercial arrival of New Day Skin Spray, a prescription topical product for management of atopic dermatitis and dry skin whose regulatory status illustrates an important distinction in dermatology: despite being used therapeutically and dispensed by prescription, New Day Skin Spray is an FDA-cleared medical device rather than an FDA-approved drug. The product was cleared under the 510(k) pathway as K252568 in January 2026 and is now reaching patients in an initial launch through Evolved Health Inc. and specialty pharmacy partner PHILRx.
The distinction matters because the evidentiary and regulatory standards applied to the product differ from those used for a new molecular entity, biologic or topical prescription medicine submitted through a drug application. FDA determined New Day Skin Spray to be substantially equivalent to the legally marketed EpiCeram Skin Barrier Emulsion predicate, allowing marketing under the 510(k) framework.
For Evolved By Nature, however, the commercial significance extends beyond this single dermatology product. New Day Skin Spray represents the first prescription medical application built from the company’s soluble silk fibroin platform to complete the regulatory process and reach patients, potentially providing an early proof point for a peptide-manufacturing technology the company wants to extend into additional healthcare applications.
What exactly did FDA clear New Day Skin Spray to do?
FDA’s official 510(k) documentation identifies New Day Skin Spray as a skin emulsion indicated for management of dryness of the skin and atopic dermatitis. The authorized labeling states that the product maintains a moist skin and wound environment beneficial to the healing process, while the 510(k) summary describes application of a thin layer to affected areas for as long as 28 days or until symptoms subside.
The device is listed under product code FRO with the classification name “Dressing, Wound, Drug” and is currently described as an unclassified pre-amendment device. It is intended for prescription use, making the product easy to mistake for a conventional prescription pharmaceutical if its regulatory pathway is not stated precisely.
New Day Skin Spray contains xanthan gum and silk fibroin alongside water, caprylic/capric triglyceride, glycerin, sodium benzoate and citric acid. FDA’s summary specifically notes that the product contains no corticosteroids and describes its mechanism in terms of a skin barrier, emollient, moisturizer and skin protector rather than a pharmacological immune-suppressing action.
Evolved By Nature describes the silk-derived component as forming a flexible, breathable surface architecture on application. The company argues that reinforcement of the compromised skin barrier can reduce penetration by irritants and pathogens that contribute to the atopic dermatitis flare cycle, but those mechanistic claims should be distinguished from the narrower indication and substantial-equivalence findings in FDA’s clearance documentation.
Why is 510(k) clearance different from FDA approval of an eczema drug?
A 510(k) submission is built around substantial equivalence to an appropriate legally marketed predicate device. FDA explains that the new product generally must have the same intended use and either the same technological characteristics or differences that do not introduce new questions of safety and effectiveness, supported by information showing that the new device is as safe and effective as the predicate for purposes of the substantial-equivalence determination.
For New Day Skin Spray, the primary predicate was EpiCeram Skin Barrier Emulsion, identified as K052643. FDA found the intended uses sufficiently comparable and concluded that the differences in formulation and delivery system did not create new safety or effectiveness questions that prevented substantial equivalence.
That means the clearance should not be described as FDA approval of a new peptide drug for atopic dermatitis. It also does not establish the same type of efficacy claim that might be expected from randomized pivotal drug trials designed to demonstrate improvement in validated disease-severity endpoints.
Instead, the regulatory record focuses heavily on device characterization and safety-related testing. FDA’s 510(k) summary states that New Day Skin Spray underwent testing covering biocompatibility, design specifications, preservative effectiveness, microbial characteristics, human repeated-insult patch testing and skin-prick testing, with the submitted data supporting substantial equivalence to EpiCeram.
What does the silk fibroin formulation add to the product?
The technological difference between New Day Skin Spray and its predicate is one of the more interesting aspects of the clearance. FDA’s comparison identifies the New Day formulation as containing silk fibroin and using an emulsion spray delivery system, whereas the predicate is a different skin-barrier emulsion with a composition including petrolatum, dimethicone, ceramide-related material, cholesterol and other ingredients.
Evolved By Nature has spent years developing methods for converting silk protein into functional materials and describes its platform as capable of manufacturing peptide-based materials at substantial scale. The company said in its August commercialization announcement that its production capability has reached 900 metric tons annually and that artificial intelligence is now being used to accelerate characterization and development across its molecular library. Those broader platform assertions remain company-reported and should not be read as findings made by FDA regarding future medical applications.
New Day Skin Spray nevertheless provides the platform with something materially different from laboratory or industrial validation: a finished prescription product whose specific formulation has passed through a US medical-device regulatory pathway.
That could help Evolved By Nature and affiliated product developers assess whether other barrier-focused or topical medical applications can be generated from the same manufacturing base. Each additional regulated use would still require its own appropriate evidence and regulatory strategy, so the first clearance does not confer approval or clearance on other molecules in the platform.
Where could New Day Skin Spray fit in atopic dermatitis management?
Atopic dermatitis treatment has become increasingly sophisticated, spanning moisturization and barrier management, topical anti-inflammatory medicines, systemic therapies and biologics for patients with disease requiring greater control. New Day Skin Spray enters that landscape as a prescription non-steroidal barrier-management product rather than as another systemic immunomodulator.
That positioning could make tolerability, ease of application, compatibility with other treatment regimens and real-world symptom management important commercial questions. The spray format may also differentiate the product operationally from creams and ointments, although superiority in adherence or outcomes cannot be assumed from delivery format alone.
The initial market launch is being conducted by Evolved Health in partnership with PHILRx, with broader availability planned after the select-market introduction.
For clinicians and payers, the more meaningful evidence will now come from use beyond the regulatory submission. Data on patient adherence, symptom trajectories, flare frequency, adjunctive use with pharmacologic therapies and comparative performance could determine whether the product becomes a niche barrier-management option or a more widely incorporated component of prescription dermatology.
The regulatory achievement is therefore notable, but its meaning needs to remain precise. New Day Skin Spray is not a newly FDA-approved eczema medicine; it is a prescription medical device that FDA found substantially equivalent to an existing skin-barrier product. What makes the development interesting is that a silk fibroin-based platform has crossed from materials technology into regulated patient use, providing Evolved By Nature with its first tangible healthcare commercialization test.
